Rare Virus-Linked cancer study tests multiple drug combos
NCT ID NCT00092222
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This study looks at a rare, often fatal disease called KSHV-associated multicentric Castleman's disease (MCD). It aims to understand how the disease works and test several experimental treatments, including high-dose zidovudine, valganciclovir, bortezomib, rituximab, and interferon. About 75 adults will participate, undergoing extra blood draws and tumor biopsies. The study may not directly help participants but could improve future treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.